Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

Phase 1 studies with PSI-7851 in the first quarter of 2009;

-- Report interim results from INFORM-1 trial in second quarter of 2009;

-- Report interim results from 28 day add-on study with R7128 in non-responder, HCV genotype 2 and genotype 3 patients in first half of 2009;

-- Report interim results from 28 day add-on study with R7128 in treatment naive, HCV genotype 1 patients in first half of 2009;

-- Report phase 1 antiviral data with PSI-7851 in second half of 2009.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe, among other countries. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. Pharmasset also anticipates initiating phase 1 studies with its second generation nucleotide inhibitor for HCV, PSI-7851 in the first quarter of 2009.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    '/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Cellgen Diagnostics today launched ... a corporate lab for its genetic-based medical testing ... a critical component in the move from today’s ... of personalized medicine – a more predictive, preventive, ... contributions will support Cellgen’s intent to develop the ...
(Date:8/19/2014)... CA (PRWEB) August 19, 2014 Robin ... Parkinson’s disease can take on an individual. Symptoms ... decreased facial expression, problems swallowing and severe depression. ... the dying off of dopamine producing neurons of the ... from a disease that slowly and progressively gets worse, ...
(Date:8/19/2014)... Aug. 19, 2014 Research ... of the "Spectroscopy Equipment and Accessories ... to their offering. This ... Equipment and Accessories in US$ Thousands by ... spectrophotometers, Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2
... VIENNA, Austria, November 28 f-star, an antibody,engineering company ... Modular Antibody Technology, today announced that it,has raised EUR ... of its Series,A financing round, originally co-led by Aescap ... raised in the Series A round,increases to EUR 9.0 ...
... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
... November 28 The results of a,study on ... desensitisation product, which is due to receive German ... VO52.06, which was carried out on 280,patients in ... the main evaluation criterion by,demonstrating a statistically significant ...
Cached Biology Technology:Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 2Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S 3Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study 2
(Date:8/19/2014)... To improve students, chances of completing introductory ... of Houston (UH) implemented a comprehensive student success ... for failure. , Through a grant from ... Department of Biology and Biochemistry embarked on a ... Biology" for non-majors and "Introductory Biology" for science ...
(Date:8/19/2014)... It,s not a lemur. It,s not an African Bush Baby ... tiny, adorable and downright "cool" primate from Southeast Asia. , ... with," said Rafe Brown, curator-in-charge at the University of Kansas, ... extremely cute, furry body; a long tail with a furry ... tips that look a bit like the disks on the ...
(Date:8/19/2014)... a biomarker strongly associated with basal-like breast cancer, ... many types of chemotherapy. The biomarker, a protein ... therapeutics designed to treat this often deadly cancer. ... The Cancer Genome Atlas, molecular biologists Curt M. ... and bioinformatics techniques to detect patterns of gene ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Biomarker in an aggressive breast cancer is identified 2Biomarker in an aggressive breast cancer is identified 3
... The decline of large predators and other "apex consumers" at ... the planet. The finding is reported by an international ... of the journal Science . The study looked ... and marine ecosystems and concluded "the loss of apex consumers ...
... 14, 2011 Two studies published in the current ... that consuming in-shell pistachios is a weight-wise approach to ... curb consumption and decrease calorie intake. ... pistachios ate 41-percent fewer calories compared to those who ...
... East Coast may be at risk to higher sea levels ... years, according to a new study by NOAA. The ... surges along the East Coast during the 2009-2010 El Nio ... NOAA,s Center for Operational Oceanographic Products and Services, examined water ...
Cached Biology News:Loss of large predators caused widespread disruption of ecosystems 2Loss of large predators caused widespread disruption of ecosystems 3In-shell pistachios: The original 'slow food?' 2In-shell pistachios: The original 'slow food?' 3Strong El Niño could bring increased sea levels, storm surges to US East Coast 2
... Universal Vacuum System UVS400 is a multi-tasking ... UVS400 combines a refrigerated vapor trap and ... single integrated unit. The easy-to-use, wide-mouth glass ... into single jar for easy disposal. The ...
... 2 products into 1:, , A multi-tube ... kit , ,The FastPrep System consists ... System Matrix and Isolation Kits. Samples are ... eliminating the use of metal probes and ...
... is a chromogenic substrate ... plasmids. In the presence ... lac + bacterial ... recombinant colonies appear white. ...
... The LCMS-2010EV is a fully flexible ... including conventional HPLC, high-speed HPLC, 1-D and ... prep scale separations. It incorporates a drying ... mist for high sensitivity, especially for low-to-medium ...
Biology Products: